Aclidinium bromide for the treatment of chronic obstructive pulmonary disease

Vandana Gupta; Dave Singh

doi:10.1586/ers.12.61

Aclidinium bromide for the treatment of chronic obstructive pulmonary disease

Vandana Gupta, Dave Singh

Research output: Contribution to journal › Article › peer-review

Abstract

Chronic obstructive pulmonary disease is characterized by poorly reversible airflow obstruction. Long-acting bronchodilators improve lung function and relieve dyspnea. Aclidinium bromide is a novel long-acting antimuscarinic bronchodilator; Phase III clinical trials have demonstrated that administration of this drug twice per day improves lung function, dyspnea and health-related quality of life. Aclidinium bromide is delivered using the Genuair ® device, which is an easy to use multidose dry powder inhaler. Aclidinium bromide is rapidly metabolized in the plasma, so there is low systemic exposure that minimizes the anticholinergic side effects. This new long-acting bronchodilator provides effective bronchodilation with minimal side effects. © 2012 Expert Reviews Ltd.

Original language	English
Pages (from-to)	581-588
Number of pages	7
Journal	Expert review of respiratory medicine
Volume	6
Issue number	6
DOIs	https://doi.org/10.1586/ers.12.61
Publication status	Published - Dec 2012

Keywords

aclidinium bromide
anticholinergics
bronchodilator
chronic obstructive pulmonary disease
lung function

Access to Document

10.1586/ers.12.61

Cite this

@article{9294165fc1734f78ac101663990f56d2,

title = "Aclidinium bromide for the treatment of chronic obstructive pulmonary disease",

abstract = "Chronic obstructive pulmonary disease is characterized by poorly reversible airflow obstruction. Long-acting bronchodilators improve lung function and relieve dyspnea. Aclidinium bromide is a novel long-acting antimuscarinic bronchodilator; Phase III clinical trials have demonstrated that administration of this drug twice per day improves lung function, dyspnea and health-related quality of life. Aclidinium bromide is delivered using the Genuair {\textregistered} device, which is an easy to use multidose dry powder inhaler. Aclidinium bromide is rapidly metabolized in the plasma, so there is low systemic exposure that minimizes the anticholinergic side effects. This new long-acting bronchodilator provides effective bronchodilation with minimal side effects. {\textcopyright} 2012 Expert Reviews Ltd.",

keywords = "aclidinium bromide, anticholinergics, bronchodilator, chronic obstructive pulmonary disease, lung function",

author = "Vandana Gupta and Dave Singh",

year = "2012",

month = dec,

doi = "10.1586/ers.12.61",

language = "English",

volume = "6",

pages = "581--588",

journal = "Expert review of respiratory medicine",

issn = "1747-6348",

publisher = "Taylor & Francis",

number = "6",

}

TY - JOUR

T1 - Aclidinium bromide for the treatment of chronic obstructive pulmonary disease

AU - Gupta, Vandana

AU - Singh, Dave

PY - 2012/12

Y1 - 2012/12

N2 - Chronic obstructive pulmonary disease is characterized by poorly reversible airflow obstruction. Long-acting bronchodilators improve lung function and relieve dyspnea. Aclidinium bromide is a novel long-acting antimuscarinic bronchodilator; Phase III clinical trials have demonstrated that administration of this drug twice per day improves lung function, dyspnea and health-related quality of life. Aclidinium bromide is delivered using the Genuair ® device, which is an easy to use multidose dry powder inhaler. Aclidinium bromide is rapidly metabolized in the plasma, so there is low systemic exposure that minimizes the anticholinergic side effects. This new long-acting bronchodilator provides effective bronchodilation with minimal side effects. © 2012 Expert Reviews Ltd.

AB - Chronic obstructive pulmonary disease is characterized by poorly reversible airflow obstruction. Long-acting bronchodilators improve lung function and relieve dyspnea. Aclidinium bromide is a novel long-acting antimuscarinic bronchodilator; Phase III clinical trials have demonstrated that administration of this drug twice per day improves lung function, dyspnea and health-related quality of life. Aclidinium bromide is delivered using the Genuair ® device, which is an easy to use multidose dry powder inhaler. Aclidinium bromide is rapidly metabolized in the plasma, so there is low systemic exposure that minimizes the anticholinergic side effects. This new long-acting bronchodilator provides effective bronchodilation with minimal side effects. © 2012 Expert Reviews Ltd.

KW - aclidinium bromide

KW - anticholinergics

KW - bronchodilator

KW - chronic obstructive pulmonary disease

KW - lung function

U2 - 10.1586/ers.12.61

DO - 10.1586/ers.12.61

M3 - Article

C2 - 23234445

SN - 1747-6348

VL - 6

SP - 581

EP - 588

JO - Expert review of respiratory medicine

JF - Expert review of respiratory medicine

IS - 6

ER -

Aclidinium bromide for the treatment of chronic obstructive pulmonary disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this